Christopher K Hwang1, George Baker Hubbard1, Louis Rapkin2, Hans E Grossniklaus3. 1. Department of Ophthalmology, Emory University School of Medicine, Atlanta, Ga., USA. 2. Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga., USA. 3. Department of Ophthalmology, Emory University School of Medicine, Atlanta, Ga., USA; Department of Pathology, Emory University School of Medicine, Atlanta, Ga., USA.
Abstract
BACKGROUND/AIMS: To report a case of subretinal bone formation after the treatment with denosumab for a giant cell tumor of the sphenoid, which had recurred after surgical resection. METHODS: The clinical history and fundus findings including imaging, histologic and immunohistochemical features of the primary tumor and subretinal lesion were reviewed. RESULTS: A 14-year-old boy was evaluated for a suprasellar mass. Resection of the lesion showed giant cell tumor of bone (GCT). An MRI study at the 1-month follow-up appointment showed tumor progression, and denosumab was initiated. Two months after the initial presentation, the patient developed a worsening scotoma of the right eye. Dilated fundus examination showed a yellow-tan-colored subretinal mass temporal to the fovea. The subretinal lesion was removed and showed lamellar bone with associated fibrocellular tissue. CONCLUSION: Denosumab therapy for GCT of the sphenoid may be associated with subretinal bone formation.
BACKGROUND/AIMS: To report a case of subretinal bone formation after the treatment with denosumab for a giant cell tumor of the sphenoid, which had recurred after surgical resection. METHODS: The clinical history and fundus findings including imaging, histologic and immunohistochemical features of the primary tumor and subretinal lesion were reviewed. RESULTS: A 14-year-old boy was evaluated for a suprasellar mass. Resection of the lesion showed giant cell tumor of bone (GCT). An MRI study at the 1-month follow-up appointment showed tumor progression, and denosumab was initiated. Two months after the initial presentation, the patient developed a worsening scotoma of the right eye. Dilated fundus examination showed a yellow-tan-colored subretinal mass temporal to the fovea. The subretinal lesion was removed and showed lamellar bone with associated fibrocellular tissue. CONCLUSION:Denosumab therapy for GCT of the sphenoid may be associated with subretinal bone formation.
Entities:
Keywords:
Denosumab; Giant cell tumor of the sphenoid; Subretinal bone formation
Authors: Daniel G Branstetter; Scott D Nelson; J Carlos Manivel; Jean-Yves Blay; Sant Chawla; David M Thomas; Susie Jun; Ira Jacobs Journal: Clin Cancer Res Date: 2012-06-18 Impact factor: 12.531
Authors: Kevin A Raskin; Joseph H Schwab; Henry J Mankin; Dempsey S Springfield; Francis J Hornicek Journal: J Am Acad Orthop Surg Date: 2013-02 Impact factor: 3.020